TABLE 2

Treatment Responses to FOLFOX and Changes in ¹⁸F-FLT Uptake

	RECIST 1.0 response achieved				Assessment with ¹⁸F-FLT PET
Patient no.	No. of target lesions	Percentage change in tumor size	After 3 cycles of FOLFOX	Best overall response	Lesion	Baseline SUV_MAX	Percentage change of SUV_MAX on day 2	Percentage change of SUV_MAX on day 5
1	5	−25.7	Stable disease	Partial response	Lymph node	5.6	69.6	5.4
2	2	−2.3	Stable disease	Stable disease	Peritoneum	5.3	107.5	−3.8
3	2	−12.8	Stable disease	Partial response	Peritoneum	2.5	380.0	24.0
4	3	−25.0	Stable disease	Partial response	Lymph node	3.1	48.4	80.6
5	1	−16.7	Stable disease	Partial response	Lung	1.7	5.9	0.0
6	1	−18.8	Stable disease	Partial response	Lymph node	5.4	131.5	181.5
7	4	−48.3	Partial response	Partial response	Lung	1.2	41.7	−16.7
8	4	8.7	Progressive disease^*	Progressive disease	Lung	2.6	69.2	−34.6
9	5	−51.9	Partial response	Complete response	Lymph node	5.2	36.5	−67.3
10	5	−23.2	Stable disease	Stable disease	Lymph node	8.7	73.6	−21.8
11	3	−46.0	Partial response	Partial response	Lymph node	7.2	45.8	−76.4
12	6	−23.3	Stable disease	Partial response	Lung	1.7	52.9	5.9
13	4	−30.7	Partial response	Partial response	Lymph node	5.1	19.6	−23.5
14	2	−8.3	Stable disease	Stable disease	Peritoneum	10.3	141.7	36.9
15	3	−31.4	Partial response	Partial response	Lung	4.7	42.6	−10.6
16	2	−8.3	Stable disease	Stable disease	Lymph node	3.7	2.7	−16.2
17	2	−27.3	Stable disease	Partial response	Lung	2.0	10.0	15.0
18	9	−13.3	Stable disease	Partial response	Lymph node	11.3	17.7	36.3

↵* Patient showed unequivocal progression of nontarget lesions after 3 cycles of FOLFOX.